THOR - Synthorx, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
19.92
+2.51 (+14.42%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close17.41
Open17.50
Bid19.50 x 900
Ask20.00 x 1300
Day's Range17.40 - 20.50
52 Week Range11.00 - 20.50
Volume168,121
Avg. Volume111,376
Market Cap624.741M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-20.21
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est28.67
Trade prices are not sourced from all markets
  • GlobeNewswire2 months ago

    Synthorx Appoints Andrew Powell, J.D., to its Board of Directors

    Synthorx, Inc. (THOR), a biotechnology company using a first-of-its-kind Expanded Genetic Alphabet platform technology to discover and develop optimized biologics for cancer and autoimmune disorders, today announced the appointment of Andrew Powell, J.D., to its board of directors. In addition, current board member Pratik Shah, Ph.D., has been appointed chairman of the board.

  • GlobeNewswire2 months ago

    Synthorx Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

    Synthorx, Inc. (THOR), a biotechnology company using a first-of-its-kind Expanded Genetic Alphabet platform technology to discover and develop optimized biologics for cancer and autoimmune disorders, today announced the closing of its previously announced initial public offering of 13,699,636 shares of common stock, which includes the exercise in full of the underwriters’ option to purchase 1,786,909 additional shares of common stock, at a public offering price of $11.00 per share. Jefferies LLC, Leerink Partners LLC and Evercore ISI acted as joint book-running managers for the offering. H.C. Wainwright & Co., LLC acted as lead manager for the offering.

  • GlobeNewswire2 months ago

    Synthorx Announces Pricing of Initial Public Offering

    Synthorx, Inc. (THOR), a biotechnology company using a first-of-its-kind Expanded Genetic Alphabet platform technology to discover and develop optimized biologics for cancer and autoimmune disorders, today announced the pricing of its initial public offering of 11,912,727 shares of common stock at a public offering price of $11.00 per share.  Synthorx anticipates total gross proceeds of approximately $131 million, before deducting underwriting discounts and commissions and other offering expenses. All shares of common stock are being offered by Synthorx. In addition, Synthorx has granted the underwriters a 30-day option to purchase up to an additional 1,786,909 shares of common stock at the initial public offering price.

  • Stocks pare losses, Nasdaq closes in the green
    Yahoo Finance2 months ago

    Stocks pare losses, Nasdaq closes in the green

    Stocks pared losses after enduring a rollercoaster session ignited after the arrest of a Chinese telecommunications company executive muddled prospects of a U.S.-China trade resolution.

  • Benzinga2 months ago

    IPO Outlook For The Week: Proteins, Fashion And Finance

    For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . Mogu Inc. (MOGU) will issue 4.75 million shares between $14 and $16 Wednesday on the New York Stock Exchange. The Chinese ...